Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients

Eiko Yamada, Ritsuo Takagi, Yoshinari Tanabe, Hiroshi Fujiwara, Naoki Hasegawa, Shingo Kato

Research output: Contribution to journalArticle

1 Citation (Scopus)


Objective: We studied the relationships between plasma and saliva concentrations of antiretroviral drugs to explore whether saliva can be used for therapeutic drug monitoring (TDM). Methods: Abacavir (ABC), tenofovir (TFV), darunavir (DRV), and raltegravir (RAL) in plasma and saliva from 30 HIV-1-infected patients were quantified using liquid chromatography-tandem mass spectrometry. Results: Mean salivato- plasma concentration ratios were 0.623 (ABC), 0.024 (TFV), 0.065 (DRV), and 0.0135 (RAL), which agree with the plasma protein binding rates except TFV. Significant correlations were evident between saliva and plasma concentrations of ABC, DRV, and RAL. Conclusions: This study suggests that plasma concentrations of ABC, DRV, and RAL can be estimated from their saliva concentrations and that the saliva concentration of some antiretroviral drugs reflects the unbound drug concentration in plasma.

Original languageEnglish
Pages (from-to)567-570
Number of pages4
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Issue number7
Publication statusPublished - 2017



  • Antiretroviral therapy
  • HIV-1 infection
  • Pre-exposure prophylaxis
  • Saliva
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology
  • Pharmacology (medical)

Cite this